What's Happening?
Lantern Pharma Inc. has announced a successful outcome from a Type C meeting with the U.S. Food and Drug Administration (FDA) regarding its HARMONIC Phase 2 trial of LP-300. The trial focuses on never-smokers with advanced non-small cell lung cancer (NSCLC)
adenocarcinoma. The FDA raised no objections to key protocol amendments proposed by Lantern, which include enriching enrollment for patients with EGFR exon 21 L858R mutations, extending LP-300 dosing to a maximum of eight cycles, and transitioning to a single-arm study design. These changes aim to provide a clearer regulatory path and enhance the trial's focus on a high-need patient population. The HARMONIC trial evaluates LP-300 in combination with carboplatin and pemetrexed, targeting a distinct subset of NSCLC patients who have experienced disease progression after treatment with kinase inhibitors.
Why It's Important?
The FDA's support for the protocol amendments is significant as it provides a more focused regulatory path for Lantern Pharma's LP-300, potentially offering a new treatment option for a specific subset of NSCLC patients. This development is crucial as never-smoker NSCLC is increasingly recognized as a distinct disease entity with unique clinical features. The trial's focus on the EGFR exon 21 L858R mutation, which is associated with inferior outcomes on current therapies, could lead to improved treatment strategies for this patient group. The amendments also aim to enhance the trial's efficiency and data quality, potentially accelerating the development of LP-300 and its commercial potential.
What's Next?
Lantern Pharma plans to continue enrolling patients in the HARMONIC trial at clinical sites in the United States and Taiwan, with completed enrollment in Japan. The company is exploring collaboration and partnering opportunities to maximize the commercial potential of LP-300 globally. Additional clinical data updates from the trial, including outcomes in the enriched EGFR exon 21 L858R cohort, are expected in the second half of 2026. The transition to a single-arm design and extended dosing cycles are anticipated to generate more focused and decision-enabling data for regulators and potential partners.
